Summary

Market Summary:
As per Market Research Future analysis, the Japan Neurodegenerative Disease Market Size was estimated at 5.12 USD Billion in 2024. The Japan neurodegenerative disease market is projected to grow from 5.51 USD Billion in 2025 to 11.46 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 7.5% during the forecast period 2025 - 2035

Market Drivers:
The aging population in Japan is a critical driver for the neurodegenerative disease market. As the demographic shifts towards an older age group, the incidence of neurodegenerative diseases such as Alzheimer's and Parkinson's is expected to rise. Currently, approximately 28% of the Japanese population is aged 65 and older, a figure projected to increase to 38% by 2050. This demographic trend suggests a growing need for effective treatments and care solutions within the neurodegenerative disease market. Furthermore, the increasing life expectancy, which stands at around 84 years, further exacerbates the prevalence of these diseases, thereby driving demand for innovative therapies and healthcare services tailored to this aging cohort. Rising awareness and education regarding neurodegenerative diseases play a pivotal role in shaping the market landscape. In Japan, initiatives aimed at educating the public and healthcare professionals about the symptoms and early detection of these diseases are gaining traction. This increased awareness is likely to lead to earlier diagnoses, which can significantly impact treatment efficacy.

Market Segment Analysis:
In the Japan neurodegenerative disease market, Alzheimer's Disease holds the largest market share among all other segment values, reflecting its significant prevalence and awareness in the population. Meanwhile, Parkinson's Disease is noted for its rapid growth, which indicates increasing visibility, advancements in treatment options, and enhanced patient support systems contributing to market expansion. The growth trends for Alzheimer's and Parkinson's Diseases are driven by several factors, including an aging population and heightened focus on early diagnosis and intervention. Increased investment in research and development for innovative therapies and medications is also facilitating growth, along with government support for mental health and neurological conditions. The rising incidence and prevalence of these conditions are shaping the market dynamics significantly. Alzheimer's Disease: Dominant vs.

Regional Analysis:
The neurodegenerative disease market in Japan is currently experiencing notable developments, driven by an aging population and increasing awareness of these conditions. As the demographic landscape shifts, the prevalence of diseases such as Alzheimer's and Parkinson's is expected to rise, prompting a greater focus on research and treatment options. The Japanese government has recognized the urgency of addressing these health challenges, leading to enhanced funding for research initiatives and the development of innovative therapies. Furthermore, collaboration between public and private sectors appears to be fostering advancements in diagnostic tools and treatment methodologies, which may improve patient outcomes. In addition to demographic factors, the neurodegenerative disease market is influenced by technological advancements in healthcare.

Major Players:
The following companies are key participants in the Japan Neurodegenerative Disease Market, playing a crucial role in market development through technological innovation, strategic partnerships, and competitive product offerings.

ページTOPに戻る

Table of Contents

TABLE OF CONTENT

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
EXECUTIVE SUMMARY
Market Overview
Key Findings
Market Segmentation
Competitive Landscape
Challenges and Opportunities
Future Outlook

2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
MARKET INTRODUCTION
Definition
Scope of the study
Research Objective
Assumption
Limitations
RESEARCH METHODOLOGY
Overview
Data Mining
Secondary Research
Primary Research
Primary Interviews and Information Gathering Process
Breakdown of Primary Respondents
Forecasting Model
Market Size Estimation
Bottom-Up Approach
Top-Down Approach
Data Triangulation
Validation

3 SECTION III: QUALITATIVE ANALYSIS
MARKET DYNAMICS
Overview
Drivers
Restraints
Opportunities
MARKET FACTOR ANALYSIS
Value chain Analysis
Porter's Five Forces Analysis
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of New Entrants
Threat of Substitutes
Intensity of Rivalry
COVID-19 Impact Analysis
Market Impact Analysis
Regional Impact
Opportunity and Threat Analysis

4 SECTION IV: QUANTITATIVE ANALYSIS
Japan Neurodegenerative Disease Market Segmentation
Japan Neurodegenerative Disease Market By Disease Type (USD Billion, 2019-2035)
Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Huntington's Disease
Japan Neurodegenerative Disease Market By Diagnosis Method (USD Billion, 2019-2035)
Neurological Examination
Imaging Techniques
Cerebrospinal Fluid Analysis
Electrophysiological Tests
Japan Neurodegenerative Disease Market By Treatment Type (USD Billion, 2019-2035)
Medication
Therapy
Rehabilitation
Surgical Interventions
Japan Neurodegenerative Disease Market By Route of Administration (USD Billion, 2019-2035)
Oral
Injectable
Intravenous
Transdermal
Japan Neurodegenerative Disease Market By Regional (USD Billion, 2019-2035)
North America
Europe
South America
Asia Pacific
Middle East and Africa
Japan Neurodegenerative Disease Market SECTION V: COMPETITIVE ANALYSIS
Competitive Landscape
Overview
Competitive Analysis
Market share Analysis
Major Growth Strategy in the Neurodegenerative Disease Market Overview
Competitive Benchmarking
Leading Players in Terms of Number of Developments in the Neurodegenerative Disease Market Overview
Key developments and growth strategies
New Product Launch/Service Deployment
Merger & Acquisitions
Joint Ventures
Major Players Financial Matrix
Sales and Operating Income
Major Players R&D Expenditure. 2023
Company Profiles
Takeda Pharmaceutical Company Limited
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Astellas Pharma Inc.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Eisai Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
On
Pharmaceutical Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Daiichi Sanky
Company, Limited
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Mitsubishi Tanabe Pharma Corporation
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Chugai Pharmaceutical Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Sumitom
Dainippon Pharma Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Appendix
References
Related Reports

ページTOPに戻る

List of Tables/Graphs

LIST OF TABLES
LIST OF ASSUMPTIONS
Japan NEURODEGENERATIVE DISEASE MARKET OVERVIEW SIZE ESTIMATES; FORECAST
TABLE 1 BY DISEASE TYPE, 2026-2035 (USD Billion)
TABLE 2 BY DISEASE TYPE, 2026-2035 (USD Billion)
TABLE 3 BY DIAGNOSIS METHOD, 2026-2035 (USD Billion)
TABLE 4 BY DIAGNOSIS METHOD, 2026-2035 (USD Billion)
TABLE 5 BY TREATMENT TYPE, 2026-2035 (USD Billion)
TABLE 6 BY TREATMENT TYPE, 2026-2035 (USD Billion)
TABLE 7 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Billion)
TABLE 8 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Billion)
PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
ACQUISITION/PARTNERSHIP

LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 JAPAN NEURODEGENERATIVE DISEASE MARKET OVERVIEW ANALYSIS BY DISEASE TYPE
FIGURE 3 JAPAN NEURODEGENERATIVE DISEASE MARKET OVERVIEW ANALYSIS BY DIAGNOSIS METHOD
FIGURE 4 JAPAN NEURODEGENERATIVE DISEASE MARKET OVERVIEW ANALYSIS BY TREATMENT TYPE
FIGURE 5 JAPAN NEURODEGENERATIVE DISEASE MARKET OVERVIEW ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 6 KEY BUYING CRITERIA OF NEURODEGENERATIVE DISEASE MARKET OVERVIEW
FIGURE 7 RESEARCH PROCESS OF MRFR
FIGURE 8 DRO ANALYSIS OF JAPAN NEURODEGENERATIVE DISEASE MARKET OVERVIEW
FIGURE 9 DRIVERS IMPACT ANALYSIS: JAPAN NEURODEGENERATIVE DISEASE MARKET OVERVIEW
FIGURE 10 RESTRAINTS IMPACT ANALYSIS: JAPAN NEURODEGENERATIVE DISEASE MARKET OVERVIEW
FIGURE 11 SUPPLY / VALUE CHAIN: JAPAN NEURODEGENERATIVE DISEASE MARKET OVERVIEW
FIGURE 12 JAPAN NEURODEGENERATIVE DISEASE MARKET OVERVIEW, BY DISEASE TYPE, 2024 (% SHARE)
FIGURE 13 JAPAN NEURODEGENERATIVE DISEASE MARKET OVERVIEW, BY DISEASE TYPE, 2024 TO 2035 (USD Billion)
FIGURE 14 JAPAN NEURODEGENERATIVE DISEASE MARKET OVERVIEW, BY DIAGNOSIS METHOD, 2024 (% SHARE)
FIGURE 15 JAPAN NEURODEGENERATIVE DISEASE MARKET OVERVIEW, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Billion)
FIGURE 16 JAPAN NEURODEGENERATIVE DISEASE MARKET OVERVIEW, BY TREATMENT TYPE, 2024 (% SHARE)
FIGURE 17 JAPAN NEURODEGENERATIVE DISEASE MARKET OVERVIEW, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
FIGURE 18 JAPAN NEURODEGENERATIVE DISEASE MARKET OVERVIEW, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
FIGURE 19 JAPAN NEURODEGENERATIVE DISEASE MARKET OVERVIEW, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
FIGURE 20 BENCHMARKING OF MAJOR COMPETITORS